Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Long-Term Investments (2023 - 2025)

Maxcyte (MXCT) has disclosed Long-Term Investments for 3 consecutive years, with $52.6 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 46.92% to $52.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.6 million through Dec 2025, up 46.92% year-over-year, with the annual reading at $52.6 million for FY2025, 46.92% up from the prior year.
  • Long-Term Investments for Q4 2025 was $52.6 million at Maxcyte, up from $52.3 million in the prior quarter.
  • The five-year high for Long-Term Investments was $52.6 million in Q4 2025, with the low at $18.4 million in Q3 2023.
  • Average Long-Term Investments over 3 years is $40.7 million, with a median of $42.6 million recorded in 2024.
  • The sharpest move saw Long-Term Investments skyrocketed 132.23% in 2024, then decreased 19.12% in 2025.
  • Over 3 years, Long-Term Investments stood at $42.9 million in 2023, then fell by 16.67% to $35.8 million in 2024, then surged by 46.92% to $52.6 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $52.6 million, $52.3 million, and $38.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.